Abstract. The results of several genome-wide association studies (GWASs) in the field of Alzheimer's disease (AD) have recently been published. Although these studies reported in detail on single-nucleotide polymorphisms (SNPs) and the neighboring genes with the strongest evidence of association with AD, little attention was paid to the rest of the genome. However, complementary statistical and bio-informatics approaches now enable the extraction of pertinent information from other SNPs and/or genes which are only nominally associated with the disease risk. Two different tools (the ALIGATOR and GenGen/KEGG software packages) were used to analyze a large GWAS dataset containing 2,032 AD cases and 5,328 controls. Convergent outputs from the two gene set enrichment approaches suggested an immune system dysfunction in AD. Furthermore, although these statistical approaches did not adopt a priori hypotheses concerning a biological function's putative role in the disease process, genes associated with AD risk were overrepresented in the "Alzheimer's disease" KEGG pathway. In conclusion, a systematic search for biological pathways using GWAS data set seems to comfort the primary causes already suspected but may specifically highlight the importance of the immune system in AD.
INTRODUCTION
Although mutations in the amyloid-β protein precursor (AβPP), presenilin-1, and presenilin-2 genes have been shown to account for most cases of the early-onset, autosomal dominant forms of AD, the latter account for less than 1% of all AD cases [1] . The genetics of the common form of AD appear to be far more complex and the only unequivocally established genetic risk factor until now was the ε4 allele of the apolipoprotein E (APOE) gene [2] .
As is the case in most multifactorial diseases, researchers investigating the genetics of AD have turned to high-throughput or very high-throughput genotyping to analyze case-control studies of hundreds of thousands of polymorphisms. However, the initial genomewide association studies (GWASs) of case-control collections in AD each examined a relatively small number of cases. To circumvent this limitation, we and others recently performed two large, independent GWASs on over 14,000 individuals. Both studies yielded compelling evidence to suggest that the clusterin (CLU), complement component (3b/4b) receptor 1 (CR1), and phosphatidylinositol-binding clathrin assembly protein (PICALM) genes are all associated with AD risk [3, 4] . Nevertheless, if the estimate that 60-80% of AD risk is due to genetic factors is correct, additional genetic susceptibility loci remain to be identified [3] [4] [5] .
It is important to bear in mind that conventional GWA approaches are primarily based on the application of a highly conservative Bonferroni correction, which ultimately selects only the most highly statistically significant associations. Accordingly, it is legitimate to consider that the "missing" genetic determinants were probably rejected on purely statistical grounds, since they only presented a nominal association with the disease risk. This limitation can be overcome by using meta-analyses of GWASs to gain statistical power (as already been successfully performed in obesity or hypertension, for instance) [6] [7] [8] . Other recently developed, complementary statistical and bioinformatics approaches are also capable of extracting pertinent information from SNPs and/or genes nominally associated with disease risk [9] [10] [11] [12] .
We decided to perform this type of comprehensive analysis on our GWAS dataset. Our main hypothesis was that the genetic determinants of AD are concentrated within one or more specific biological pathways, rather than being randomly distributed. Several methods exist for ranking gene pathways in terms of their involvement in disease susceptibility. A number of computer programs have been developed to test for overrepresentation of gene ontology (GO) categories (e.g., biological processes) in lists of significant SNPs produced in GWASs. We used the ALIGATOR software to analyze our single-SNP GWAS dataset. This method takes account of multiple sources of potential bias, such as linkage disequilibrium between SNPs, variable gene size, overlapping genes. and non-independent GO categories [13] .
However, ALIGATOR (like most techniques based on GO category analysis) is limited by the fact that each functional category is analyzed independently; there is no unifying analysis at the pathway or system level. Furthermore, less than 1% of the GO annotations have been confirmed experimentally [14] . In order to take account of these limitations, we also used the GenGen software package to perform pathway-based analysis of GWA data. This approach is based on use of the KEGG database to detect the over-representation of genes from a specific pathway. It also enables one to define the position of the associated genes in a given pathway [9, 15, 16] .
MATERIALS AND METHODS
The GWAS [3] Genomic DNA samples from 2,344 AD cases were available for analysis, prior to genotype quality control steps. All AD cases were evaluated by neurologists from Bordeaux, Dijon, Lille, Montpellier, Paris, and Rouen and were identified as French Caucasian. A clinical diagnosis of probable AD was established according to the DSM-III-R and NINCDS-ADRDA criteria. Genomic DNA samples of 7,076 controls were available from the 3C study, prior to genotype quality control steps. These controls were known to be dementiafree after four years of follow-up. The 3C Study is a population-based, prospective study of the relationship between vascular factors and dementia. It has been carried out in three French cities: Bordeaux (southwest France), Montpellier (south France), and Dijon (central eastern France). A sample of non-institutionalized, over-65 subjects was randomly selected from the electoral rolls of each city between January 1999 and March 2001 [17] . Written, informed consent was obtained from study participants or, for those with substantial cognitive impairment, from a caregiver, legal guardian, or other proxy. The study protocols were reviewed and approved by the appropriate institutional review boards. DNA samples were transferred to the French National Genotyping Center (CNG) for genotyping. First-stage samples that passed DNA quality control procedures were genotyped with Illumina Human 610-Quad BeadChips. Samples that had been successfully genotyped for > 98% of the SNP markers were selected for inclusion in the study. SNPs with a call rate < 98%, a minor allele frequency (MAF) < 1% or exhibiting departure from Hardy-Weinberg equilibrium in the control population (p< 10 −6 ) were excluded. On the basis of these genetic data, we removed 134 AD cases and 980 control samples because they were found to be first-or seconddegree relatives of other study participants or of nonEuropean descent. This process resulted in selection of 537,029 autosomal SNPs genotyped in 2,032 AD cases (mean age: 73.7 ± 8.9; mean age at onset: 68.3 ± 9.0, 34% men), and 5,328 controls (mean age: 73.8 ± 5.4; 34% men).
The SNP-to-gene mapping file
For both ALIGATOR and GenGen analyses (see URLs), gene and SNPs information data for chromosome 1-22 were extracted from NCBI ftp websites (respectively reference assembly, build 36.3 and dbSNP, build 130). Pseudogenes were systematically excluded from analyses. A SNP located between the 5' and 3' ends of the first and last exons of a gene was always assigned to the latter. A SNP located within 20kb of the 5' and 3' ends of the first and last exons of a gene was assigned to the latter, in order to take account of putative regulatory (i.e., expression-modulating) regions. However, if a given SNP was assigned to more than one gene, all the entries were re-analyzed.
ALIGATOR analyses
The ALIGATOR software was developed to test for over-representation of biological pathways (as indexed by GO terms) in lists of significant SNPs from GWASs. The software was implemented and used as described [13] . To define the p values of SNP associations, we used logistic regression to evaluate case vs. control differences. In order to take potential population stratification into account, this process optionally incorporated principal components that were significantly associated with disease status [3] . On the basis of a file containing the full set of our GWAS results (29, 200 SNPs nominally associated with the AD risk at p < 0.05), three p value categories were then examined (< 0.01, < 0.001, and < 0.0001) ( Table 1) . As recommended by the tutorial on the ALIGATOR website, we generated up to 50,000 replicate genelists. The replicate genelists, generated from randomly-sampled SNPs, are used to calculate the category-specific pvalue. We also tested different numbers of replicate studies (1,000, 2,000, or 5,000). These replicate studies are used to assess significance of the numbers of categories reaching various p-values, as well as studywide significance levels for individual categories which are corrected for testing multiple non-independent GO categories. This latter parameter slightly modified the results. The data presented in the present report were derived from 50,000 replicate genelists and 1,000 replicate studies.
GWA KEGG pathway analyses
We used the GenGen package as described in the online tutorial (see URLs). To adjust for differences in gene size (i.e., different numbers of SNPs located within or near to each gene) and for linkage disequilibrium between SNPs within the same gene, a two-step correction procedure was performed. Firstly, the raw individual genotype data were analyzed by logistic regression with PLINK software. Again, potential population stratification is taken into account by optionally incorporating principal components that were significantly associated with disease status. As recommended by the software designer (see tutorial), we generated a GWA association result file including SNPs, associated chi2 and P-values for at least 1,000 phenotype permutations. At this stage, the file contained 28,866 SNPs nominally associated with AD at p < 0.05. Secondly, we applied the calculate gsea.pl program, which has been designed to perform pathway-based GWA tests on highdensity SNP genotyping data with respect to the KEGG databases (release 17 November 2009) [18] . This program uses (i) the GWA association result file, (ii) a SNP-to-gene mapping file, and (iii) a pathway annotation file to perform pathway-based association tests. The algorithm was adapted from that used in Gene Set Enrichment Analysis software [19] . The method selects the lowest p-value of all the SNPs near a gene but also uses phenotype-based permutation to adjust the statistical significance. Since pathways with only few genes and those with too many can bring some false positives, KEGG pathways containing from 10 to 200 genes were analyzed (as defined by -setmin 10 and -setmin 200 in the calculate gsea.pl program). Once the most strongly associated pathways have been identified from amongst a set of candidates, the nominal p-values are calculated from the permutation procedure and a false discovery rate (FDR) procedure has been used to control the fraction of expected false positive findings below a certain threshold. Table 1 describes the number of categories reaching significance levels of 0.01, 0.001, and 0.0001 in ALI-GATOR for over-representation in our GWAS dataset. The ALIGATOR software allows estimation whether this number of categories was obtained by chance or may results from a real over-representation. In our GWAS data set, no significant level of the excess of over-represented categories was observed (Table 1) . However, many of the most significant individual GO categories appeared to be involved in immune processes, whatever the cut-off value used to select significant SNPs from the GWA dataset (< 0.01, < 0.001, or < 0.0001) ( Table 2) .
RESULTS
As mentioned above, the use of GO annotations presents a number of limitations, particularly the lack of a unified analysis at the pathway or system level. To circumvent this limitation, we used the GenGen software package and the associated KEGG database to detect gene over-representation in a specific pathway. As recommended by GenGen's developers, we first generated a GWA result file (including SNPs and the corresponding chi2 and p values for at least 1,000 permutations) by using a co-dominant model adjusted for principal components. These data were then crosschecked against a KEGG pathway annotation file using the calculate gsea.pl program. We found that 4,776 SNPs nominally associated with the AD risk were assigned to 1,395 genes involved in 173 KEGG pathways. Following application of the FDR procedure, we identified 5 physiological or disease-related KEGG pathways displaying over-representation of genes associated with the AD risk in our GWA dataset (Table 3) .
Remarkably, the top-ranked gene set/pathway was that referenced in KEGG as "Alzheimer's disease": 46 of its 163 genes presented nominal association with the AD risk. This over-representation was significant (p = 0.001) after FDR correction (Table 4 and Fig. 1 ). We also found specific over-representation of genes involved in one or more of KEGG's immune pathways. However, in contrast to the results obtained for the KEGG "Alzheimer's disease" gene set, we observed two potential causes of artificial enrichment in the KEGG immune gene sets. Firstly, given the design of our initial analysis, it is possible that some SNPs can be assigned to different genes (see the paragraph on SNP-to-gene mapping in the Material and Methods section). This assignation can be problematic when the SNP is located within a cluster of genes involved in the same biological pathway. Secondly, some SNPs may be in linkage disequilibrium and thus will ultimately bear the same information -whereas not assigned to the same gene. In order to take into account these two sources of bias in the selected KEGG immune gene pathways, we repeated an analysis in which each SNP was assigned to only one gene (arbitrarily the closest) and by selecting only one SNP in the event of an r 2 value 0.5 when comparing different SNPs. These processes led to the exclusion of four SNPs. After having controlled for these sources of biases, we were still able to identify two KEGG immune pathways displaying the overrepresentation of genes associated with the AD risk in our GWA dataset: (i) antigen processing and presentation (p = 0.04) and (ii) regulation of autophagy (p = 0.05) ( Tables 5, 6 and 7) .
DISCUSSION
The simple GWA approach used to test hundreds of thousands of markers for association with a specific phenotype has proved to be quite successful in characterizing the major genetic determinants of certain diseases. However, the loci discovered to date do not ac- count for the complete heritability for most of the studied phenotypes. It has been suggested that since (i) GWASs are probably insufficiently powered to detect small main effects (false negatives) and (ii) gene-gene interactions are likely to play a role, the full potential of highly complex GWAS datasets may not yet have realized [6] . Gene set enrichment analyses can address this complexity by considering multiple loci simultaneously and relating them to known functional annotations. Hence, pathway analyses can lead to new discoveries overlooked in simple, single-SNP tests and thus successfully identify associations with pathways involved in pathogenesis. This context prompted us to perform gene set enrichment analyses of a GWAS dataset featuring 2,032 AD cases and 5,328 controls. Using the GenGen software 2 number of genes for which a SNP in the GWA database has been assigned. 3 number of genes presenting a SNP nominally associated with AD risk and finally retained for estimation of overrepresentation. package, we observed an over-representation of genes associated with the AD risk in the KEGG "Alzheimer's disease" pathway. Since the gene set enrichment analysis does not make any a priori hypotheses about the biological functions involved in the disease process, our findings appear to be relevant and should advance our current understanding of AD. For instance, genes coding for α-secretase (ADAM10 [20] ) or β-secretases -03  COX7B2  rs9291291  8,5E-03  NOS2A  rs3794764  9,3E-03  APP  rs462281  1,0E-02  CALM1  rs1058903  1,1E-02  PPP3CA  rs17030795  1,1E-02  CACNA1D  rs3796349  1,2E-02  NDUFS2  rs10797094  1,2E-02  NOS1  rs12099598  1,2E-02  COX7A2L  rs1981664  1,2E-02  CASP7  rs11196449  1,2E-02  LPL  rs4466415  1,3E-02  PLCB3  rs915987  1,4E-02  SDHC  rs4272646  1,6E-02  TNF  rs3132452  1,7E-02  NDUFA9  rs4147683  1,8E-02  CACNA1S  rs3767498  1,9E-02  GNAQ  rs7033572  2,0E-02  CAPN1  rs17743381  2,2E-02  UQCRC2  rs11648723  2,3E-02  NDUFV3  rs4148972  2,3E-02  GRIN2C  rs7219247  2,3E-02  ERN1  rs17688326  2,4E-02  NOS3  rs3918227  2,5E-02  COX6B2  rs11084396  2,5E-02  LRP1  rs1800159  2,6E-02  ATP5C1  rs1244447  2,7E-02  MAPK1  rs2298432  2,8E-02  UCRC  rs16988025  2,9E-02  CAPN2  rs751128  3,0E-02 (BACE1 and BACE2 [21] ) have SNPs nominally associated with the AD risk in their vicinity (i.e., in the gene itself or within 20kb of the 5' and 3' ends of the gene's first and last exons). This observation may indicate that changes in the expression or function of proteins directly involved in AβPP metabolism may slightly modify the risk of developing AD in sporadic, late-onset forms of AD. This overrepresentation of genes associated with AD risk in the "Alzheimer's disease" KEGG pathway seems also to point out Ca 2+ signaling involvement (Fig. 1) [22] . This observation is of particular interest, since much biological evidence has suggested that impaired Ca 2+ signaling is involved in the physiopathology AD (by modulating AβPP metabolism [23] or in modulating toxicity linked to amyloid-β (Aβ) peptide exposure [24] , for example).
In addition to these well-documented processes, our study suggests that the regulation of autophagy and antigen processing and presentation are also involved in AD. Autophagy has already been suspected of playing a role in AD [25] . Firstly, this biological process seems to be induced but impaired in neurons in the AD brain, since autophagic vacuoles accumulate dramatically in dystrophic neuritis [26] . Secondly, it has been suggested that autophagy can protect neurons from Aβ-induced apoptosis [27] . In fact, it is not clear whether autophagy has causative or a protective role or whether induction is a consequence of the disease process [28] .
Interestingly, endogenous presentation of an epitope derived from proteins on MHC class II can be mediated by autophagy [29] . We found that the KEGG "antigen processing and presentation" pathway also displays over-representation of the genes associated with the AD risk in our GWA dataset. One can postulate that Aβ peptides are endocytosed by antigen-presenting cells, processed into fragments that are bound to MHC molecules and presented to T lymphocytes. Antigen presentation can lead to B-cell stimulation and then production of Aβ-specific auto-antibodies. In conclusion, specific immune responses could appear to be capable of inducing Aβ degradation and may constitute a natural line of defense against harmful accumulation of the Aβ peptides. Of course, such mechanisms have been reported in Aβ peptide-immunized AD patients: individuals have shown a dramatic reduction of amyloid deposition when compared with non-immunized individuals [30] . However, natural antibodies against Aβ peptides are present in the sera of AD patients and in non demented individuals [31] . These auto-antibodies inhibit Aβ peptide aggregation in vitro [32] , and it has been observed that in non-amyloid-immunized AD patients, auto-antibodies against Aβ peptides may help reduce the plaque burden and increase the numbers of phagocytic microglia [32] . Altogether, these data can be interpreted as an Aβ peptide antibody-dependent activation of immune response. Furthermore, even if the CLU and CR1 genes are not annotated in the KEGG immune response pathways we picked-up, this hypothesis would be in accordance to our initial results in- volving CLU and CR1 as major genetic determinants of AD in influencing susceptibility to late onset forms of the disease through a role in Aβ clearance [3] . Furthermore it is worth noting that CR1 might act as either activator or inhibitor of B cell and T cell functions [33] . Interestingly CR1 is mainly expressed in the choroid plexus in the brain [34] and the choroid plexus could represent a site for lymphocyte entry in the CSF and brain, and for presentation of antigens [35] . Despite these interesting results, our study suffered from the usual limitations of gene set enrichment analyses [11] . The latter tend to highlight genes that contain many SNPs or indeed any pathway that contains several large genes. Conversely, these analyses tend to overlook pathways that only contain small genes. To compensate for this problem, we used two approaches based on permutation testing, needed to account for this size bias. Furthermore, the quality of the biological databases used in gene set enrichment approaches strongly influences the relevance of the resulting outputs. We addressed this specific point by using two different databases: GO and KEGG. The GO database mainly relies on computer prediction but also includes human annotation. It provides a broad spectrum of gene sets for testing enrichment. However, as previously mentioned, GO annotation analyses are limited (i) by the fact that each functional category is analyzed independently (in the absence of a unifying analysis at the pathway or system level) and (ii) because less than 1% of the GO annotations have been confirmed experimentally [14] . This is why we also used the KEGG pathway database; in contrast to GO, it is manually compiled on the basis of biological evidence [17] . Interestingly, both approaches highlighted the innate immune system (even though the over-representation of the immune GO categories in the ALIGATOR analyses was not significant). Furthermore, the fact that we observed significant enrichment of genes featured in the "Alzheimer's disease" gene set supports the pertinence of our results. Lastly, gene set enrichment approaches have (in part) been developed to detect potential genetic determinants that are rejected on purely statistical grounds as a result of only nominal associations with the disease risk. However, it is likely that false positive associations are also included in these analyses and may lead to biased gene set enrichment by chance. Even though this specific point is difficult to assess, we crosschecked our data with the results obtained in another recent large AD GWAS [4] . However, the available online data were limited, since these only included SNPs associated at 
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